How do tumor mutations help doctors select drugs for lung cancer?

Tumor mutations are critical for selecting lung cancer treatments because they reveal the specific molecular defects driving a patient's disease. By using DNA sequencing to identify these unique genetic alterations, physicians can create a molecular profile—or "bar code"—of the tumor.1

This information allows doctors to employ targeted therapies, which are drugs specifically designed to neutralize the abnormal proteins or mechanisms produced by these mutations. Because these therapies focus on the specific drivers of tumor growth rather than broadly attacking all rapidly dividing cells, they are often more effective and less toxic to healthy tissue than traditional chemotherapy.12

The identification of these mutations enables a form of personalized medicine, where treatment is tailored to the individual's unique genetic makeup. Diagnostic tests used to detect these alterations and predict drug efficacy are known as companion diagnostics. By matching a patient's specific tumor mutations to drugs designed to interfere with those exact molecular targets, clinicians can provide more precise and rational care.231